Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you, eb. I asked management to contact their colleagues now serving in the House and Senate, because they can really educate them on what is going on here. But I didn't want to impose on management to do something they might not want to do, ahead of a possible EUA decision. I just thought the doctors' caucus would be better than the House Oversight Committee in understanding how valuable lenz is. Hopefully, others here will see their Representative's name, and contact them, as well.
Even MORE hopefully, management has resubmitted our EUA application already, and we will get a positive decision.
That 2.54 Hazard Ratio, and a P value of 0.0009, is clear evidence from the peer review that the EUA should have been approved.
I would ask you to narrow that down a little, but it's not necessary. If you're talking about our readiness to recall our loaned shares, and our merger, and a CMML approval from Australia as being delusional, I went to great lengths to support the reasons for each conclusion. Can you demonstrate reasons why those conclusions are delusional?
If you're talking about me securing the services of someone to run my household, I hope to have enough financial success from our short squeeze to be able to find someone that might be interested in doing so. I just know that I can't do things for myself anymore, and I don't want to sell my property and rent an apartment. So at least wish me luck.
Sometimes, it's nice to have all the dry cleaning done, but when I look into my closet, I'm still happier to see the wash and wear clothes hanging there. (1)
My issue against the abuse of discretionary authority by government agencies causes me to, on occasion, value controllable circumstances less than I should. What's important to us right now is our preparedness to recall our loaned shares, a potential merger with Baudax, and our effort to gain regulatory approval from Australia's Therapeutic Goods Administration for the treatment of CMML.
"Humanigen and the Principal Investigator are assessing regulatory pathways that may enable
early results to support a regulatory submission and potential approval by the Therapeutic Goods Administration in Australia, which could be expanded through Project Orbis10 to the United States and the United Kingdom."
https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Presents-Promising-New-Hematologic-Data-from-PREACH-M-Trial-for-Chronic-Myelomonocytic-Leukemia-Treatment-at-the-2023-Europ-OYZCQ.pdf
I am more than ready to celebrate our success with Humanigen, which I hope is imminent.
(1) It's been years since my weekly stops at the dry cleaners, and after dumping the clean laundry on my bed, I don't manage to get everything hung, since I sleep on the couch, and don't use the bed. But there was a time when I had a normal life. Note to self: Budget for a cleaning lady with some of those big bucks you'll get in the short squeeze. If she can drive the riding lawn mower, and can cook, don't let her get away. If she can sing some country music, God will have sent me an angel.
Is there a doctor in the House?
In the 118th Congress, there are 19 of them.
https://wenstrup.house.gov/about/doctors-caucus.htm
I wrote the following to my Representative.
US Congresssman Michael C.Burgess, MD
"I am writing to you as the Co-Chair of the GOP Doctors Congress in regards to a monoclonal antibody (mAb) called lenzilumab (lenz) developed by Humanigen, which has a successful Phase III trial for the treatment of hospitalized and hypoxic covid patients, and which has still not been given Emergency Use Authorization by the FDA.
As reported in a Thorax peer review, C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial show:
"WHAT THIS STUDY ADDS
? In LIVE-AIR, elevated baseline plasma CRP was
the most predictive feature for progression
to invasive mechanical ventilation or death
(OR, 0.15; 95% CI 0.07 to 0.29; nominal
p<0.001). Participants with baseline CRP <150
mg/L represented 78% of the LIVE-AIR study
population and demonstrated the greatest
improvement in SWOV with lenzilumab,
through day 28 (HR: 2.54; 95% CI 1.46 to 4.41;
p=0.0009)."
https://thorax.bmj.com/content/thoraxjnl/early/2022/07/05/thoraxjnl-2022-218744.full.pdf
Very importantly, lenz is variant agnostic.
There is no need for variant-specific targeting.
Lenz is designed to prevent cytokine storm, which leads to the inflammation, which causes death in these patients.
This drug should be stockpiled by the US government as the only effective medical countermeasure in our therapeutic arsenal.
Please help the doctors/company executives of Humanigen to get the long-overdue approval of their Emergency Use Authorization application.
Millions of lives worldwide are being lost needlessly. The FDA needs to be held accountable, and needs to approve the company's EUA for lenzilumab.
Thank you.
Jay Booth
Rhome, TX "
Oh my gosh, eb, I don't think I've ever seen anyone post that before. But what better opportunity could there be?
I liken it to the financing arrangement we had with Hercules. I don't think it affects our deal, which is likely geared more to developing the Treg treatment market opportunities with TeraImmune.
Baudax entered into a Purchase Agreement with Alumni Capital for $50M.
https://www.sec.gov/Archives/edgar/data/1780097/000119312523220763/d516324dex101.htm
https://www.alumnicapital.com/
The $326M the government has awarded to Regeneron, "... for a next-generation antibody therapy for prevention of infections," has me curious.
I'll just cut to the chase. Is this an infringement of one of our recent patents?
"METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY
Publication number: 20230109208
Abstract: The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Type: Application
Filed: March 8, 2021
Publication date: April 6, 2023
Applicant: HUMANIGEN, INC.
Inventors: Cameron DURRANT, Dale CHAPPELL"
https://patents.justia.com/assignee/humanigen-inc
I refer to this as our lenz/vaccine/anti-viral cocktail when writing about it.
We're dealing with US regulatory agencies who have total disregard for the millions of deaths lenz could have prevented, and could still prevent, if they had authorized our product.
Urging approval action from HHS or any Executive Branch agency would be a waste of time.
Cameron and Dale, can you contact the 17 members of the Legislative Branch who are medical doctors serving in the House or Senate? Perhaps you can set up a Zoom meeting presentation. This impacts the constituents of all 17 members.
"As several physicians run for Congressional office in 2022, it's worth noting their 17 colleagues who hold medical degrees and serve in the 117th U.S. Congress.
Four physicians currently serve as senators, and 13 serve as representatives.
Meet the 17 physicians in the 117th U.S. Congress:
1. Ami Bera, MD: Dr. Bera is a general practice physician who serves as the democratic representative for California's 7th District, and has been in office since 2013.
2. Larry Bucshon, MD: Dr. Bucshon is a thoracic surgeon who serves as the Republican representative for Indiana's 8th District, and has been in office since 2011.
3. Michael Burgess, MD: Dr. Burgess is an OBGYN who serves as the Republican representative for Texas' 26th District, and has been in office since 2002.
4. Scott DesJarlais, MD: Dr. DesJarlais is a family medicine physician who serves as the Republican representative for Tennessee's 4th District, and has been in office since 2011.
5. Neal Dunn, MD: Dr. Dunn is a urologist who serves as the Republican representative for Florida's 2nd District, and has been in office since 2017.
6. Mark Green, MD: Dr. Green is an emergency medicine physician who serves as the Republican representative for Tennessee's 7th District, and has been in office since 2019.
7. Andy Harris, MD: Dr. Harris is an anesthesiologist who serves as the Republican representative for Maryland's 1st District, and has been in office since 2011.
8. Ronny Jackson, MD: Dr. Jackson is an emergency medicine physician who serves as the Republican representative for Texas' 13th District, and has been in office since 2020.
9. John Joyce, MD: Dr. Joyce is a dermatologist who serves as the Republican representative for Pennsylvania's 9th District, and has been in office since 2019.
10. Mariannette Miller Meeks, MD: Dr. Meeks is an ophthalmologist who serves as the Republican representative for Iowa's 2nd District, and has been in office since 2020.
11. Greg Murphy, MD: Dr. Murphy is a urologist who serves as the Republican representative for North Carolina's 3rd District, and has been in office since 2019.
12. Raul Ruiz, MD: Dr. Ruiz is an emergency medicine physician who serves as the Democratic representative for California's 36th District, and has been in office since 2013.
13. Kim Schrier, MD: Dr. Schrier is a pediatric physician who serves as the Democratic representative for Washington's 8th District, and has been in office since 2018.
14. John Barrasso, MD: Dr. Barrasso is an orthopedic surgeon who serves as a Republican senator for Wyoming.
15. Bill Cassidy, MD: Dr. Cassidy is a gastroenterologist who serves as a Republican senator for Louisiana.
16. Roger Marshall, MD: Dr. Marshall is an OBGYN who serves as a Republican senator for Kansas.
17. Rand Paul, MD: Dr. Paul is an ophthalmologist who serves as a Republican senator for Kentucky."
Thank you for your consideration of my request.
https://www.beckersasc.com/asc-news/the-17-physicians-in-the-117th-us-congress.html
Thank you so much for that research, sosjtb.
I actually wasn't worried about losing quotation services, even though they have never been more valuable to us than now, on the (figurative) eve of the recall of our loaned shares.
But management showed their support of my position against discretionary authority vested in regulatory agencies, and how it manifested in that grant to Regeneron, for instance. And I'm sure they knew I would consider today's Baudax filings as an indication that we remain on track with our merger, and they were right. Management values their shareholders, sosjtb, and they don't want us to walk out, just as the show is about to start. I find the Baudax filings very reassuring, and I hope that you are also reassured. You should be especially reassured by finding the information you have shared with us. I, for one, very much appreciate it.
My way of looking at any SEC filing from Baudax is as a step closer to our merger with them. They made two more filings just now.
https://www.sec.gov/Archives/edgar/data/1780097/000119312523220227/d738302d8a12g.htm
https://www.sec.gov/ix?doc=/Archives/edgar/data/1780097/000119312523220231/d229243d8k.htm
I didn't want to be submissive of your concern, especially since I don't know what the reporting requirements, etc., are for Pink Limited companies, if that's what we are.
But if we are falling apart, I don't think management at Humanigen and Baudax share that assessment. I'm seeing an "All systems go" signal in that regard.
But this whole subject came up at the same time that I was reacting to the news of the $1.4B the government was awarding Big Pharma for developing new covid therapeutics and vaccines, "...including a $326 million contract with Regeneron Pharmaceuticals for a next-generation antibody therapy for prevention of infections.
The funding to Regeneron is a part of a $5 billion initiative dubbed "Project NextGen" by the U.S. Department of Health and Human Services (HHS)."
https://www.yahoo.com/news/us-govt-awards-1-4-194306288.html
It's enough to make one apoplectic. And I think management may likewise have been overcome with anger at that news. But their anger would have been fueled even further, because they KNOW that lenzilumab can save even more lives that will be lost, all because lenzilumab is being withheld from the market.
It's like the blue collar anthem of Oliver Anthony says, "it's a damn shame."
https://www.google.com/search?q=oliver+anthony+lyrics&sca_esv=559765737&source=hp&ei=babnZKDWCKquqtsPyfmuEA&iflsig=AD69kcEAAAAAZOe0feEWDn716xA6sRhpqwJ5U19RF5f9&oq=oliver&gs_lp=Egdnd3Mtd2l6IgZvbGl2ZXIqAggGMgsQLhiKBRixAxiDATIIEC4YigUYkQIyCBAuGIoFGJECMgQQABgDMgsQLhiKBRixAxiDATILEC4YgAQYsQMYgwEyBBAAGAMyBBAuGAMyCxAuGIAEGLEDGIMBMgQQABgDSP1RUIUKWMAWcAF4AJABAJgBrQGgAfEEqgEDNS4xuAEByAEA-AEBqAIKwgIXEAAYigUY6gIYtAIYigMYtwMY1AMY5QLCAggQABiKBRiRAsICCBAuGLEDGIAEwgILEAAYgAQYsQMYgwHCAg4QLhiABBixAxjHARjRA8ICERAuGIAEGLEDGIMBGMcBGNEDwgIREC4YigUYsQMYxwEY0QMYkQLCAggQABiABBixA8ICBRAAGIAEwgIIEC4YgAQYsQPCAggQABiABBjJA8ICCBAAGIoFGJID&sclient=gws-wiz#fpstate=ive&vld=cid:001e0201,vid:7ojbrRG7BU4
I'll be watching GH in particular. If I see any indication of trouble, I will point it out. That's a promise.
If we are well passed the 5 day window...but we are still trading...then there is something about the allowed extension you mention, that is not apparent.
And again, IF we are trading Pink Limited, how would reporting requirements pertain here?
I see no sign of surrender by management. Quite the contrary, it looks like their focus remains on a successful recall of their loaned shares, for the full benefit of shareholders, for the entire amount of our OS, with no 40% carve out for a business combination. But I do think we will merge with Baudax, and quickly regain Nasdaq listing compliance with this merger.
The irony is beyond toleration of this search by the government to find a therapeutic that they already have, to alleviate public health and medical infrastructure concerns, that they themselves are allowing by negligently ignoring lenzilumab's authorization application.
"Then there's BA.2.86, which has been nicknamed Pirola and has more mutations than any of the other variants currently circulating — more than 30 — and has already been detected at least twice in the United States. But despite what experts call high outbreak potential, it's not the variant currently driving the current surge. Nonetheless, SARS-CoV-2, the virus that causes COVID, does one thing really well and that's mutate to evade our immune defenses. What the fall will look like in terms of COVID cases is yet to be seen, but things are not looking good as hospitalizations, infections and deaths are all on the rise. The latest vaccine updates can't get here soon enough — if people even decide to take them."
https://www.yahoo.com/news/covid-19-variants-driving-surge-222302021.html
Dear government, The $1.4B in awards that Humanigen shareholders/taxpayers are helping to pay for new covid therapies and vaccines, could be used to restore our Market Cap to where it was before the FDA granted themselves the power to "Decline" to make decisions on covid products, such as our lenzilumab, and the government could have the variant-agnostic lenz cocktail vaccine, and the therapeutic, that you will never find anywhere else but with Humanigen. Azzholes.
"US govt awards $1.4 billion for development of new COVID therapies, vaccines
Reuters
Tue, August 22, 2023"
Nothing mentioned about Humanigen
https://www.yahoo.com/news/us-govt-awards-1-4-194306288.html
"...the new BA.2.86 lineage of coronavirus may be more capable than older variants in causing infection in people who have previously had COVID-19 or who have received vaccines."
This is exactly what Geert Vanden Bossche predicted would happen, and he expressed his concern specifically as this could impact twice-infected patients.
It looks like the embedded newscast was filmed last month, before a vote in Brevard County in regards to mainly mRNA vaccines.
Here are excerpts of the Resolution they voted upon, and a few other Florida counties also voted upon. I'm glad it is noted that both covid, and mRNA covid vaccines, are viewed as bioweapons.
https://www.theflstandard.com/brevard-county-gop-declares-covid-vaccines-bioweapons-calls-for-legal-action/
We already see news, now, about how covid vaccines are required for some college admittance. And FOX news is scoffing at measures such as mask wearing.
Perhaps surprisingly, I don't agree with the commentary from FOX news. What containment measures worked, or didn't work, as well as what vaccines and therapeutics worked, or didn't work, are irrelevant to a new variant, especially if it is a manufactured variant, at least in part.
The variant agnostic lenzilumab IS REQUIRED to treat covid pneumonia, and to maintain the innate immune response, against these variants. And I will look forward to seeing the lenz cocktail used as a preventative, as well.
I think a lot of people open up one of my posts, and see so much written, that they just go on to the next post. That's why I started doing 'ZoomLenz,' in which I try to get the main subject of my recent postings down to a single bullet point.
But I did write a two sentence post in which I used more sentence clauses in the second sentence than I have probably ever used.
"I really hope that our 10-Q will focus on the positive news that I think WE CAN CONTROL. That is, a review of our stellar CMML results, prompting the initiation of a related aGvHD trial, which could lead to a cure for certain myelodysplastic leukemias, with announcement of a share recall of our Outstanding Shares, which I think we own entirely, and the declaration of a 5:1 forward stock split, in preparation of an intended merger, resulting in the re-listing of our stock on the Nasdaq Stock Exchange."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172586987
I actually liked that post. But I wish I would have mentioned a possible CAR-T development, because I think there will be one. I should have also mentioned that I think we could end up with authorization or an approval for covid, and the effect it has on our innate immune response system. Maybe we'll see something in that regard from the study of lenz on Long Covid. And although Pfizer at least got their bone marrow cancer treatment authorized, which was more than Gilead could do, there is no way that hospital administrators aren't going to look at lenz as a much more attractive therapeutic.
I think management has placed Humanigen at the strongest defensive point possible, where positive news will take our share price farther and faster than if we were still on Nasdaq. There may be more flattening, than loading, but we'll certainly welcome new buyers, who will be jumping on the train. It could only be nicer if our lenz cocktail was ready to be revealed, and lenz was shown to prevent not only cancers, such as CMML, but covid, as well. But, the new buyers we pick up on our short squeeze will have something to look forward to, along with us.
LOL, your pessimism is overstated, or our volume wouldn't be so low. I will only allow you "scepticism," at best, and only briefly (just kidding). With our recent trial data, including the near pathway of a cure for CMML, and an EUA for covid, sitting on the 10-Q has no justification, other than to make the forced covering caused by a recall of our loaned shares as painful as possible.
I echo DTGoody's sentiment, that we will file the 10-Q, which I think is completed, except for a possible update.
That update, in my opinion, will include news that we will merge with Baudax, and avoid a business combination with them (not factor in a 40% sacrifice of our OS).
To me, this is all about announcing:
a positive regulatory update,
and, a recall of our loaned shares, in the worst possible environment for brokerages who have a short exposure of 110M shares that they will have to buy, in a much less liquid market.
I think we may have been downgraded from Pink Current to Pink Limited.
"Pink Market Tiers: Current and Limited
Within the Pink market exist tiers. Companies that fully abide by the disclosure rules are dubbed "current," whereas those who do the bare minimum under Rule 15c2-11 and are perhaps late with filings are downgraded to the “Pink Limited” market tier.
Pink Limited is essentially a demotion from the Pink current status for those who don't fully abide by Rule 15c2-11. That demotion can lead to restrictions and is generally less favorable.
When a company no longer meets the requirements for limited information, it will be moved to the Expert Market, where there are no public broker-dealer quotations."
https://www.investopedia.com/terms/p/pinksheets.asp
I entered a small sell order to see how that possible demotion affected trading, and it appeared to have no affect at all.
But it seems that a brokerage with significant short exposure could have hell in the event of a recall of loaned shares.
This is beyond my pay grade. It's a whole new chapter in the playbook for me to witness.
Thanks, DTG. So I assume that yield sign has been up since we filed the NT 10-Q.
Thanks for the link, Yooo. I got a yield sign to show up on the quote box. But I'm expecting to see that loaned shares are being recalled. I don't know what to think. Nothing shows up on my Schwab platform regarding a yield
Seriously, no kidding.
I don't see anything, sosjtb.
Is Gilead's CEO O'Day really worth the 11% bump in compensation he got, up to $21.6M?
I think Humanigen would have loved to have lenz as the treatment therapeutic in their bone marrow cancer trial. We just didn't want to give them exclusive use of lenz. So they go out and buy 'Forty Seven, Inc' for $4.9B, and now the FDA has placed the trial on clinical hold.
Meanwhile, Pfizer's bone marrow cancer treatment is targeting a $4B market for their product. And lenz sits idly by, awaiting FDA approval, for years. What a wasted opportunity for Gilead, and for Humanigen, both of whom are in Black Rock's portfolio.
More news on magrolimab.
"US FDA puts Gilead Sciences blood cancer drug studies on hold
Reuters
August 21, 2023
Gilead Sciences (GILD.O) said on Monday the U.S. health regulator placed a clinical hold on studies of its blood cancer drug, just a month after the company scrapped a late-stage trial due to efficacy concerns.
The company gained access to the drug, magrolimab, with its $4.9 billion buyout of Forty Seven Inc in March 2020.
The company said the U.S. Food and Drug Administration (FDA) had paused screening and enrollment of new study participants, while the patients already under the studies may continue to receive treatment."
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-puts-gilead-sciences-blood-cancer-drug-studies-hold-2023-08-21/
Baudax files 8-K this morning. Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
"The Purchase Agreement contains customary representations and warranties and agreements of the Company and the Purchasers and customary indemnification rights and obligations of the parties. The Company is expected to receive net proceeds of approximately $1.6 million in connection with the Offering, after deducting advisory fees and related offering expenses. The Company intends to use the net proceeds from the Offering for pipeline development activities and general corporate purposes. The closing of the Offering and the Concurrent Private Placement is expected to occur on or about August 21, 2023, subject to satisfaction of customary closing conditions.
The Shares, Series E Pre-Funded Warrants, and the shares of Common Stock issuable upon exercise of the Series E Pre-Funded Warrants in the Offering were offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-253117)..."
https://www.sec.gov/Archives/edgar/data/1780097/000119312523216610/d540795ddefa14a.htm
"
"And by the way, Baudax filed a second prospectus today."
Two different file numbers are reflected in the Registration statements. One is an S-1 filing, the other is an S-3 filing.
https://www.sec.gov/Archives/edgar/data/1780097/000119312523093995/d497372ds1.htm
https://www.sec.gov/Archives/edgar/data/1780097/000119312521043475/d46186ds3.htm
"Form S-1 – long form typically used for IPOs and sometimes for other primary and secondary sales of securities. Form S-3 – short form typically used for follow-on offerings and public resales of a company's securities by selling shareholders, and available only if eligibility requirements are met."
https://www.google.com/search?q=what+is+the+diference+between+an+S-1+and+an+S-3%3F&sca_esv=558339750&ei=g2jgZOj2Nb2wqtsPyMiwiAE&ved=0ahUKEwioxJmWk-iAAxU9mGoFHUgkDBEQ4dUDCBA&uact=5&oq=what+is+the+diference+between+an+S-1+and+an+S-3%3F&gs_lp=Egxnd3Mtd2l6LXNlcnAiMHdoYXQgaXMgdGhlIGRpZmVyZW5jZSBiZXR3ZWVuIGFuIFMtMSBhbmQgYW4gUy0zPzIFEAAYogRI8ExQhwhY2ShwAXgBkAEAmAGXAaAB-AGqAQMxLjG4AQPIAQD4AQHCAgoQABhHGNYEGLAD4gMEGAAgQeIDBRIBMSBAiAYBkAYI&sclient=gws-wiz-serp
Thank you for that info, eb.
And by the way, Baudax filed a second prospectus today.
Speaking of covid and changes in our innate immune response system:
"Friday, August 18, 2023
Severe COVID-19 may lead to long-term innate immune system changes
NIH-funded research links alterations to inflammatory protein, underscores vaccine importance...
In these experiments, some of the subjects received antibodies at the early stage of illness that prevented IL-6 from binding to cells. During recovery, these mice and people had lower levels of altered stem cell gene-expression instructions, monocyte production and inflammatory cytokine production than subjects that didn’t receive the antibody. In addition, the lungs and brains of mice that received the antibodies had fewer monocyte-derived cells and less organ damage."
I wonder which antibodies, administered early, that prevented IL-6 from binding to cells, they used. In any event, this small study seems to be based on, and validates, the lenzilumab method of action.
https://www.nih.gov/news-events/news-releases/severe-covid-19-may-lead-long-term-innate-immune-system-changes
Added again. This coming Monday was our deadline to regain Nasdaq compliance. I doubt that going to the OTC was conditional, but you never know. Besides, I think we'll qualify for Nasdaq again if we complete our business combination with Baudax.
FYI, Baudax released a prospectus.
https://www.sec.gov/Archives/edgar/data/1780097/000119312523214745/d516691d424b3.htm
I can't see a situation in which you would ever have to apologize to me for anything, even though I try to express myself more precisely in some instances, because of your counsel, but fail on times to do so.
I yield and agree to your point that lenz doesn't prevent or treat covid infection. I have been saying "covid pneumonia" every time I can remember to do so, and that is always in deference to your guidance.
So, I would like to see the reinfection rate of covid pneumonia in lenz treated patients.
Forgive me in advance if I forget to add "pneumonia" in discussing this. But it's going to be harder to do so in the future, because lenz is being touted as part of a cure in CMML cancer, because that cancer is myeloid-driven, and, although lenz doesn't treat that cancer, it prevents it by blocking the virus from attaching to GM-CSF.
Restoring the body's immune response is an element of discussion I have seen in regards to the use of lenz. I think keeping the integrity of our immune response is critical, as these manufactured covid variants have the intention of changing our bodies' natural responses. I think we'll learn more about this as we continue to develop our lenz/vaccine/anti-viral cocktail, as well as we incorporate TeraImmune's TReg development.
Besides all else, I want to have, and express, the fullest appreciation of lenzilumab's potential. Management is not positioned to speculate. They can only state facts that are proven, in my opinion. So there's no way anything I say is going to be 100% accurate. And I'm glad to see that you recognize that.
Always, always, appreciate hearing from you, eb.
I got focused on your deficient immune numbers on my initial response to your post, and did not address the short squeeze you mentioned that we longs are hoping for.
My interest in this company was because I knew from the short squeeze the company had previously, that government agencies were abusing their discretionary authority here. While that is almost always fatal to the victimized company, there are a very few company managers who know how to capitalize on regulatory complacency. We have such managers. I saw that when I read the filing that described their share structure.
The short squeeze is imminent. An article written about our first short squeeze noted that a key takeaway was, "Fundamentals are not important in a short squeeze situation."
https://www.reddit.com/r/GME/comments/lo5pvo/this_is_what_a_short_squeeze_looks_like_come_and/?rdt=57254
The heavy lifting has already been done. Management has already bought back every share they have issued, and they are ready to recall their loaned shares, which will force shorts to cover because they sold the borrowed shares. I'm as sure of this as I can be.
Thanks, eb. The subject of lenzilumab restoring the immune response system is developing in our trial data. I think it is hugely important, and will become even more so.
But, the covid re-infection rate in lenz patients is also something I have long thought is hugely important, and I don't see any data on that yet, after all this time.
I'm looking forward to learning more on both subjects. I'd even like to have the raw data to be able to make those determinations, if it is not something that is being analyzed.
I'm scheduled for a procedure in the doctor's office in the morning, either an angioplasty or a stent into the artery near my left hip, to remove a plaque build-up. I could be home by noon. Nothing says "get well soon" like a short squeeze. Did I get that right? Maybe it's a quick hug, but I'm pretty sure I'd get better faster with a short squeeze.
Maybe it was even before the LIVE-AIR trial commenced, and all we had to go by were studies, but I knew that lenz could have helped my wife. Management knew that lenz would be effective when used with remdesivir and dexamethasone. None of that mattered, and my wife's condition deteriorated.
No, it is not my job to be Inspector Clouseau. But it's my self-appointed job to support the effort to get this drug to other patients, like my wife was.
Worthless doctors don't bring a cancer cure to market, nor even a potential covid cure.
Black Horse took an 8.24% stake in Baudax for 500K shares, at about $0.69 per share.
https://money.cnn.com/quote/shareholders/shareholders.html?symb=bxrx&subView=institutional
From what I see, at this point, Humanigen stands ready to execute the merger with Baudax.